Tata Medical and Diagnostics Ltd (TataMD) is a new healthcare venture from the Tata group, India’s largest business conglomerate. TataMD aims to provide leading-edge, patient-centric solutions, with a clear vision to make healthcare accessible and reliable.
TataMD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR-based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers.
Our vision is to be a trusted, long-term partner and help shape the evolution of healthcare towards more inclusive and integrated patient-centric solutions that are delivered to consumers using the innovative hybrid ‘Bridgital’ model.
By investing in robust partnerships and collaborative frameworks with global industry leaders and research organizations, TataMD will help build world-class science and technical capabilities as well as drive use of digital technologies to ensure “connected care” for patients.
As a company launched during the 2020 pandemic, one defining priority for TataMD was to develop, launch and scale the availability of affordable diagnostics to treat COVID-19. Our first product is the world’s first commercially available CRISPR Cas-9 based COVID-19 test. It is powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute, and will be the new standard for COVID-19 diagnostics. In the future, TataMD CHECK diagnostics will be extended to other diseases and medical applications as a comprehensive diagnostic tool.
TataMD CHECK - The New Standard for Testing
TataMD CHECK test is the NEW standard in COVID-19 diagnosis - Simple, Reliable and Scalable.
Using high quality testing kits manufactured at its plant, the TataMD CHECK testing experience is simpler and delivers quicker results. The TataMD CHECK test detects the virus with high accuracy and delivers accurate diagnosis.
Based on FELUDA CRISPR Cas-9 genomic technology, TataMD CHECK is an ICMR-approved and DCGI-certified, highly COVID-19 viral detection test with a sensitivity and specificity that is at par with qPCR.
This will enable more healthcare providers to fast-track COVID diagnosis services to more people and also allow other NABL-certified diagnostic centres to offer COVID-19 testing solutions.
Based on CRISPR genomic technology, TataMD CHECK is an ICMR-approved and DCGI-certified, highly Covid-19 viral detection test with a sensitivity and specificity that is at par with qPCR.
TataMD Check’s simpler, more agile testing process delivers quick results and enables more patients to be tested by bringing diagnostics closer to the patient. Testing can be performed swiftly and in small batches using simple, inexpensive, off-the-shelf thermocyclers instead of expensive qPCR equipment. This will enable diagnostic labs to achieve higher test throughputs and scale up volumes with minimal capital investments and set-up time.
TataMD CHECK test kits have a continuous quality-controlled process from factory-to-laboratory that uses sensors to monitor temperatures and ensure kits remain tamper-proof. Test results are analysed by AI software based on the visual reading on the paper strip and published automatically through a cloud platform.
For real-time reliability and transparency across the value chain for patients, healthcare providers and authorities, the TataMD CHECK test-lifecycle is backed by an integrated digital process. This approach includes dedicated apps for partners and patients, AI-driven software insights and verifiable patient records hosted on the Cloud.
TataMD CHECK will be especially useful in rapid turnaround situations like airports, hospitals, universities, and camps where quick delivery of results is critical in order to reduce waiting times for patients.
TataMD CHECK will be especially useful in rapid turnaround situations like airports, hospitals, universities, and camps where quick delivery of results is critical in order to reduce waiting times for patients. Accessible and accurate results will allow for better testing strategies that mean people can return to everyday activities.
TataMD will produce the test kits under secure, state-of-the-art production facility (facilities) in Tamil Nadu, India that has been commissioned with a capacity of 10 million test kits. The company is building a strong distribution network through partnerships with trade channels and direct sales.
The TataMD CHECK test has been developed for commercial use by Tata’s in-house team of scientific and research professionals, based on CSIR-IGIB’s FELUDA platform.